Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis

Natarajan, Yamini; Tansel, Aylin; Patel, Parth; Emologu, Kingsley; Shukla, Richa; Qureshi, Zeeshan; El–Serag, Hashem B.; Thrift, Aaron P.; Kanwal, Fasiha

doi:10.1007/s10620-020-06498-7

Cited by 34 publications

(28 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reported incidences of PBC-related HCC range from 2.4 to 6.6 cases per 1000 patient-years, which is two times higher in males than that in females [ 67 , 68 , 171 – 173 ]. A recent meta-analysis showed that the PBC-related HCC incidence was 5.77 per 1000 person-years in Asia, which was similar to that in North America (5.10 per 1000 person-years), but higher than that in Europe(2.67 per 1000 person-years) [ 174 ].…”

Section: Management Of Pbcmentioning

confidence: 99%

APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis

You

Efe

et al. 2022

Hepatol Int

View full text Add to dashboard Cite

show abstract

Section: Management Of Pbcmentioning

confidence: 99%

APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis

You

Efe

et al. 2022

Hepatol Int

View full text Add to dashboard Cite

show abstract

“…Cirrhosis is the predominant risk factor for the development of HCC, with an incidence rate of 10.07 per 1000 person-years in patients with AIH cirrhosis. Other risk factors associated are older age, increased frequency of relapses, concurrent alcohol consumption, and a trend for male sex [15][16][17][18][19][20] . Asian populations are also observed to have an increased incidence of HCC, suggesting an influence of genetic and environmental factors [15] .…”

Section: Autoimmune Liver Diseases and The Risk Of Hepatocellular Carcinomamentioning

confidence: 99%

Autoimmune liver diseases, hepatocellular carcinoma, and recurrence of autoimmunity post-liver transplantation

Wang¹,

Dong²,

Montaño-Loza³

et al. 2021

View full text Add to dashboard Cite

Liver transplantation for the autoimmune liver diseases (AILD), which includes autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), is indicated in the setting of decompensated cirrhosis, liver failure, and hepatocellular carcinoma (HCC). The risk of HCC is thought to be low in AILD, though data on the risk factors and predictors of HCC are limited in this population. Recurrence of AILD can occur in over half of the patients, complicating the post-transplant course. The pathogenesis of recurrent AILD involves a complex interaction of genetic and environmental influences, as well as a variety of clinical risk factors. Graft and patient survival are negatively impacted by recurrent AILD and the optimal approach to the treatment of AILD recurrence is the subject of ongoing research. This review will address the current literature on the risk of HCC in AILD, as well as the development and management of recurrent AILD post-liver transplantation.

show abstract

“…We report a high risk of HCC in viral hepatitis and a lower risk in ALD and autoimmune liver disease consistent with previous findings. 9 , 11 , 15 , 32 A Canadian study from a single hepatology center in Toronto 10 found that HCC occurred most often in individuals with viral hepatitis (incidence rate 23/1000 person‐years). Their 5‐ and 10‐year cumulative incidences were in line with our results.…”

Section: Discussionmentioning

confidence: 99%

The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population‐based cohort study

et al. 2022

View full text Add to dashboard Cite

Background Current risk estimates for hepatocellular carcinoma (HCC) in individuals with cirrhosis vary between studies. The risk has mostly been evaluated for single etiologies separately. Objectives We examined the risk of HCC in Swedish outpatients with a new diagnosis of cirrhosis, aiming to identify subgroups with a particularly high risk for incident HCC. Methods All patients with a first diagnosis of cirrhosis in the National Outpatient Register for whom the etiology of cirrhosis could be estimated were identified. Incident cases of HCC were ascertained until the end of 2016 using record linkage to national registers. The cumulative incidence of HCC across etiologies of cirrhosis, sex and age was calculated considering non‐HCC death as a competing risk. Results We identified 15,215 individuals with cirrhosis. The incidence rate for HCC in cirrhosis was 23/1000 person‐years (95%CI = 22–24). Stratified on gender, it was 29/1000 person‐years (95%CI = 27–31) in men versus 14/1000 person‐years (95%CI = 13–16) in women. The cumulative incidence of HCC in cirrhosis was 8.3% (95%CI = 7.8–8.8) at 5 years and 12.2% (95%CI = 11.6–13.0) at 10 years. At 10 years, the lowest cumulative incidence was seen in women with alcohol‐related liver disease (4.3%) and the highest in men with viral hepatitis (26.6%). These figures also varied by age. Conclusions The risk of HCC differs extensively across subgroups of etiologies of cirrhosis, age and sex, suggesting that initiation of HCC surveillance could be individually tailored.

show abstract

Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis

Cited by 34 publications

References 45 publications

APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis

APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis

Autoimmune liver diseases, hepatocellular carcinoma, and recurrence of autoimmunity post-liver transplantation

The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population‐based cohort study

Contact Info

Product

Resources

About